基于免疫检查点阻断的治疗彻底改变了癌症治疗。尽管取得了显着的成功，并且针对其他检查点的多种检查点抑制剂的临床前开发也已完成，但只有针对 PD-1/PD-L1 轴和 CTLA-4 的抗体已被批准用于患者治疗，特别是实体瘤。目前，随着Relatlimab的批准，第三种LAG-3阻断抗体已被用于抗击癌症。 relatlimab 的认可标志着癌症免疫治疗的一个重要里程碑，为联合治疗和增强治疗效果开辟了新途径。然而，LAG-3 复杂的生物学特性可能会阻碍其作为治疗替代品的全面发展。在这篇综述中，我们深入了解 LAG-3 的生物学及其在癌症治疗方面当前和未来的发展。© 2024。作者。

Treatment based on immune checkpoint blockade has revolutionized cancer therapy. Despite the remarkable success achieved and the preclinical development of multiple checkpoint inhibitors targeting other checkpoints, only antibodies targeting the PD-1/PD-L1 axis and CTLA-4 have been approved for patient treatment, especially in solid tumors. Currently, with the approval of relatlimab, a LAG-3 blocking antibody, a third player, has been used in the fight against cancer. The endorsement of relatlimab marks a significant milestone in cancer immunotherapy, opening new avenues for combination therapies and enhancing treatment outcomes. However, the complex biology of LAG-3 may hinder its full development as a therapeutic alternative. In this review, we provide in-depth insight into the biology of LAG-3 and its current and future development in cancer treatment.© 2024. The Author(s).